Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANYSNAKES antivenom comparison study for snakebite
ISRCTN13332106Phase 3Recruiting
- Sponsor
- Liverpool School of Tropical Medicine
- Start
- Mar 2026
- Modality
- Fab Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of EchiTAb Plus ICP, Antivipmyn, PANAF-Premium, inoserp and EchiTAb G in snakebite envenomation (6 arms), sponsored by Liverpool School of Tropical Medicine. Primary endpoints: Primary endpoint for shock cohort, Primary endpoint for coagulopathy cohort and 1 more. Started Mar 2026; status: recruiting.
02
Drugs
EchiTAb Plus ICPAntivipmynPANAF-PremiuminoserpEchiTAb G
03
Conditions
snakebite envenomation
Beyond the preview
Go deeper on ISRCTN13332106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN13332106.